A randomised phase III study on the treatment of children and adolescents with refractory or relapsed acutye myeloid leukemia (AML).

Trial Profile

A randomised phase III study on the treatment of children and adolescents with refractory or relapsed acutye myeloid leukemia (AML).

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2013

At a glance

  • Drugs Daunorubicin liposomal (Primary) ; Cytarabine; Doxorubicin liposomal; Filgrastim; Fludarabine; Granulocyte colony-stimulating factors
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jan 2013 Primary endpoint 'Haematological-response-rate' has been met.
    • 11 Nov 2010 Last checked against Netherlands Trial Register record.
    • 18 Dec 2009 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top